Apitolisib Less Effective Than Everolimus for mRCC

Share this content:
Apitolisib was less effective than everolimus in patients with metastatic renal cell carcinoma.
Apitolisib was less effective than everolimus in patients with metastatic renal cell carcinoma.

Apitolisib, a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR), was less effective than everolimus, an mTOR inhibitor, in patients with metastatic renal cell carcinoma (mRCC), a study published in the Journal of Clinical Oncology has shown.1

For the open-label, phase 2 study, researchers enrolled 85 patients with clear cell mRCC who progressed on or after a vascular endothelial growth factor (VEGF) inhibitor, such as sorafenib, sunitinib, or pazopanib. Participants were randomly assigned to receive apitolisib 40 mg orally once daily or everolimus 10 mg orally once daily.

Results showed that median progression-free survival was 3.7 months with apitolisib compared with 6.1 months with everolimus (HR, 2.12; 95% CI, 1.23 - 3.63; P < .01), suggesting that risk of progression or death is more than twice as likely with apitolisib as with everolimus. Further, subgroup analyses demonstrated that apitolisib was less effective in every stratification subgroup.

Researchers found that median overall survival was 16.5 months with apitolisib vs 22.8 months with everolimus (HR, 1.77; 95% CI, 0.97 - 3.24; P = .06). Overall survival was not significantly different between the 2 groups, but researchers observed a trend toward everolimus. Objective response rate was 7.1% and 11.6% for apitolisib and everolimus, respectively.

In terms of safety, apitolisib was associated with substantially more high-grade hyperglycemia and rash than everolimus. Thirty-one percent and 12% of patients in the apitolisib and everolimus groups, respectively, discontinued treatment due to grade 3 to 4 adverse events.

Researchers also conducted retrospective biomarker marker analyses, which revealed that hypoxia-inducible factor 1α protein expression was associated with improved outcome in both treatment arms. VHL mutation status was also associated with outcome in the everolimus group, but not the apitolisib arm.

RELATED: Percutaneous Ablation for Small Renal Masses Appears Safe, Effective

These findings suggest that VHL mutation and hypoxia-inducible factor 1α expression may be predictive of an mTOR inhibitor benefit; however, prospective validation is necessary.


  1. Powles T, Lackner MR, Oudard S, et al. Randomized open-label phase II trial of apitolisib (GDC-0980), a novel inhibitor of the pi3k/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma [published online ahead of print March 7, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.64.8808.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs